Modality
Multispecific
MOA
CAR-T BCMA
Target
CD38
Pathway
RNA Splicing
Wet AMDMDS
Development Pipeline
Preclinical
~Aug 2015
→ ~Nov 2016
Phase 1
~Feb 2017
→ ~May 2018
Phase 2
Aug 2018
→ May 2031
Phase 2Current
NCT07116316
2,824 pts·Wet AMD
2023-05→2031-05·Completed
NCT03684404
2,903 pts·Wet AMD
2018-08→2025-09·Recruiting
5,727 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-09-166mo agoPh2 Data· Wet AMD
2026-08-104mo awayEnrollment Complete· Wet AMD
2031-05-025.1y awayPh2 Data· Wet AMD
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2
Recruit…
P2
Complet…
Catalysts
Ph2 Data
2025-09-16 · 6mo ago
Wet AMD
Enrollment Complete
2026-08-10 · 4mo away
Wet AMD
Ph2 Data
2031-05-02 · 5.1y away
Wet AMD
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07116316 | Phase 2 | Wet AMD | Completed | 2824 | ORR |
| NCT03684404 | Phase 2 | Wet AMD | Recruiting | 2903 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 |